{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:13:34Z","timestamp":1788581614478,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ard.2026.05.033","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:02:53Z","timestamp":1783656173000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A head-to-head comparison of abatacept and adalimumab in adults with early and dual seropositive rheumatoid arthritis plus HLA-DRB1 shared epitope: results from the randomised phase 3 AMPLIFIED trial"],"prefix":"10.1016","author":[{"given":"Paul","family":"Emery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E","family":"Weinblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian P","family":"Bykerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6735-5496","authenticated-orcid":false,"given":"Andrew P","family":"Cope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3724-1874","authenticated-orcid":false,"given":"Gustavo","family":"Citera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd R","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Dornic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathanial","family":"Eddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Buckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2026.05.033_bib0001","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers."},{"issue":"3","key":"10.1016\/j.ard.2026.05.033_bib0002","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/qjmed\/hcp165","article-title":"Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies","volume":"103","author":"Song","year":"2010","journal-title":"QJM."},{"issue":"23","key":"10.1016\/j.ard.2026.05.033_bib0003","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.ard.2026.05.033_bib0004","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3390\/ijms23020905","article-title":"Rheumatoid arthritis: pathogenic roles of diverse immune cells","volume":"23","author":"Jang","year":"2022","journal-title":"Int J Mol Sci."},{"issue":"1","key":"10.1016\/j.ard.2026.05.033_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000009","article-title":"Therapeutic implications of autoantibodies in rheumatoid arthritis","volume":"2","author":"Aletaha","year":"2016","journal-title":"RMD Open."},{"issue":"7","key":"10.1016\/j.ard.2026.05.033_bib0006","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.3899\/jrheum.131341","article-title":"A metaanalysis of the increased risk of rheumatoid arthritis-related pulmonary disease as a result of serum anticitrullinated protein antibody positivity","volume":"41","author":"Zhu","year":"2014","journal-title":"J Rheumatol."},{"issue":"4","key":"10.1016\/j.ard.2026.05.033_bib0007","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/art.24390","article-title":"Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis","volume":"61","author":"L\u00f3pez-Longo","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.ard.2026.05.033_bib0008","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014945","article-title":"Anti-cyclic citrullinated peptide antibody is highly associated with rheumatoid factor and radiological defects in rheumatoid arthritis patients","volume":"98","author":"Sulaiman","year":"2019","journal-title":"Medicine (Baltimore)."},{"issue":"6","key":"10.1016\/j.ard.2026.05.033_bib0009","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1186\/s13075-014-0483-3","article-title":"Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts","volume":"16","author":"Humphreys","year":"2014","journal-title":"Arthritis Res Ther."},{"issue":"12","key":"10.1016\/j.ard.2026.05.033_bib0010","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1164\/rccm.201411-1950OC","article-title":"Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers","volume":"191","author":"Doyle","year":"2015","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.ard.2026.05.033_bib0011","doi-asserted-by":"crossref","DOI":"10.1177\/2235042X19853484","article-title":"Morbidity and mortality in patients with rheumatoid arthritis compared with an age- and sex-matched control population: a nationwide register study","volume":"9","author":"L\u00f8ppenthin","year":"2019","journal-title":"J Comorb."},{"issue":"4","key":"10.1016\/j.ard.2026.05.033_bib0012","first-page":"534","article-title":"Association of anti-citrullinated protein or peptide antibodies with left ventricular structure and function in rheumatoid arthritis","volume":"56","author":"Geraldino-Pardilla","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.ard.2026.05.033_bib0013","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/art.38307","article-title":"Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis","volume":"66","author":"Sokolove","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"10.1016\/j.ard.2026.05.033_bib0014","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/art.1780301102","article-title":"The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis","volume":"30","author":"Gregersen","year":"1987","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.ard.2026.05.033_bib0015","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.autrev.2013.08.002","article-title":"HLA shared epitope and ACPA: just a marker or an active player?","volume":"12","author":"Pratesi","year":"2013","journal-title":"Autoimmun Rev."},{"issue":"3","key":"10.1016\/j.ard.2026.05.033_bib0016","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4078\/jrd.2022.29.3.171","article-title":"Clinical implications of shared epitope and anti-citrullinated peptide antibody in patients with rheumatoid arthritis","volume":"29","author":"Jung","year":"2022","journal-title":"J Rheum Dis."},{"key":"10.1016\/j.ard.2026.05.033_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.755844","article-title":"Toward overcoming treatment failure in rheumatoid arthritis","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol."},{"issue":"12","key":"10.1016\/j.ard.2026.05.033_bib0018","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1136\/annrheumdis-2018-213687","article-title":"Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey","volume":"77","author":"Roodenrijs","year":"2018","journal-title":"Ann Rheum Dis."},{"issue":"24","key":"10.1016\/j.ard.2026.05.033_bib0019","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.3390\/jcm13247594","article-title":"Unmet needs and current challenges of rheumatoid arthritis: difficult-to-treat rheumatoid arthritis and late-onset rheumatoid arthritis","volume":"13","author":"Takanashi","year":"2024","journal-title":"J Clin Med."},{"issue":"1","key":"10.1016\/j.ard.2026.05.033_bib0020","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1186\/s13063-019-3403-7","article-title":"Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol","volume":"20","author":"Al-Laith","year":"2019","journal-title":"Trials."},{"issue":"6","key":"10.1016\/j.ard.2026.05.033_bib0021","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1155\/2012\/237258","article-title":"Assessment and management of pain in juvenile idiopathic arthritis","volume":"17","author":"Stinson","year":"2012","journal-title":"Pain Res Manag."},{"issue":"1","key":"10.1016\/j.ard.2026.05.033_bib0022","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","article-title":"Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"10.1016\/j.ard.2026.05.033_bib0023","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/art.37711","article-title":"Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study","volume":"65","author":"Weinblatt","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.ard.2026.05.033_bib0024","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","article-title":"Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial","volume":"75","author":"Sokolove","year":"2016","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"10.1016\/j.ard.2026.05.033_bib0025","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1038\/s41598-024-56987-2","article-title":"Association of HLA-DRB1 locus with treatment response to abatacept or TNF inhibitors in patients with seropositive rheumatoid arthritis","volume":"14","author":"Cha","year":"2024","journal-title":"Sci Rep."},{"issue":"1","key":"10.1016\/j.ard.2026.05.033_bib0026","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13075-021-02607-7","article-title":"HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA","volume":"23","author":"Rigby","year":"2021","journal-title":"Arthritis Res Ther."},{"issue":"1","key":"10.1016\/j.ard.2026.05.033_bib0027","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000564","article-title":"Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study","volume":"4","author":"Jansen","year":"2018","journal-title":"RMD Open."},{"issue":"1","key":"10.1016\/j.ard.2026.05.033_bib0028","doi-asserted-by":"crossref","first-page":"91","DOI":"10.55563\/clinexprheumatol\/g8xqxr","article-title":"Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept","volume":"39","author":"Kumar","year":"2021","journal-title":"Clin Exp Rheumatol."},{"issue":"3","key":"10.1016\/j.ard.2026.05.033_bib0029","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1016\/S2665-9913(25)00371-6","article-title":"Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial","volume":"8","author":"Cope","year":"2026","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.ard.2026.05.033_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1383110","article-title":"Abatacept increases T cell exhaustion in early RA individuals who carry HLA risk alleles","volume":"15","author":"Long","year":"2024","journal-title":"Front Immunol."},{"issue":"8","key":"10.1016\/j.ard.2026.05.033_bib0031","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","article-title":"Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"67","author":"Schiff","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.05.033_bib0032","doi-asserted-by":"crossref","first-page":"m4328","DOI":"10.1136\/bmj.m4328","article-title":"Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial","volume":"371","author":"Hetland","year":"2020","journal-title":"BMJ."},{"issue":"10","key":"10.1016\/j.ard.2026.05.033_bib0033","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/ard-2023-224116","article-title":"Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial","volume":"82","author":"\u00d8stergaard","year":"2023","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"10.1016\/j.ard.2026.05.033_bib0034","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra2103726","article-title":"Rheumatoid arthritis - common origins, divergent mechanisms","volume":"388","author":"Gravallese","year":"2023","journal-title":"N Engl J Med"},{"issue":"7987","key":"10.1016\/j.ard.2026.05.033_bib0035","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-023-06708-y","article-title":"Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes","volume":"623","author":"Zhang","year":"2023","journal-title":"Nature."},{"issue":"10","key":"10.1016\/j.ard.2026.05.033_bib0036","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41584-020-0491-4","article-title":"Transforming clinical trials in rheumatology: towards patient-centric precision medicine","volume":"16","author":"Pitzalis","year":"2020","journal-title":"Nat Rev Rheumatol."},{"issue":"10429","key":"10.1016\/j.ard.2026.05.033_bib0037","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","article-title":"Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial","volume":"403","author":"Cope","year":"2024","journal-title":"Lancet."},{"issue":"10429","key":"10.1016\/j.ard.2026.05.033_bib0038","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0140-6736(23)02650-8","article-title":"Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial","volume":"403","author":"Rech","year":"2024","journal-title":"Lancet."},{"key":"10.1016\/j.ard.2026.05.033_bib0039","unstructured":"Queen Mary University of London. 3TR Molecular PAthobiology and PRecision Therapy iN EaRly Rheumatoid Arthritis Study (3TR-PARTNER-RA). Eudract Identifier 2024-511470-79 [Internet]. 2024. Last updated 2024 [accessed April 24, 2026] Available from: https:\/\/euclinicaltrials.eu\/ctis-public\/view\/2024-511470-79-00?lang=en"},{"key":"10.1016\/j.ard.2026.05.033_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1630569","article-title":"CAR-T cell therapies in autoimmune rheumatic diseases: a brief report on the clinical trial landscape, current status, and future perspectives","volume":"16","author":"Xu","year":"2025","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.ard.2026.05.033_bib0041","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41467-022-35264-8","article-title":"Cytotoxic CD8(+) T cells target citrullinated antigens in rheumatoid arthritis","volume":"14","author":"Moon","year":"2023","journal-title":"Nat Commun."},{"issue":"1","key":"10.1016\/j.ard.2026.05.033_bib0042","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2567.2011.03470.x","article-title":"CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease","volume":"134","author":"Strioga","year":"2011","journal-title":"Immunology."},{"issue":"1","key":"10.1016\/j.ard.2026.05.033_bib0043","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/BOR.0000000000000011","article-title":"T-cell aging in rheumatoid arthritis","volume":"26","author":"Weyand","year":"2014","journal-title":"Curr Opin Rheumatol."},{"issue":"5","key":"10.1016\/j.ard.2026.05.033_bib0044","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3899\/jrheum.091176","article-title":"Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response","volume":"37","author":"Scarsi","year":"2010","journal-title":"J Rheumatol."},{"issue":"16","key":"10.1016\/j.ard.2026.05.033_bib0045","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of upadacitinib or abatacept in rheumatoid arthritis","volume":"383","author":"Rubbert-Roth","year":"2020","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.ard.2026.05.033_bib0046","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10067-013-2392-2","article-title":"Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity","volume":"33","author":"Takahashi","year":"2014","journal-title":"Clin Rheumatol."},{"issue":"8","key":"10.1016\/j.ard.2026.05.033_bib0047","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/acr2.11259","article-title":"Associations between safety of certolizumab pegol, disease activity, and patient characteristics, including corticosteroid use and body mass index","volume":"3","author":"Bykerk","year":"2021","journal-title":"ACR Open Rheumatol."},{"issue":"5","key":"10.1016\/j.ard.2026.05.033_bib0048","first-page":"653","article-title":"Association between disease activity and risk of serious infections in subjects with rheumatoid arthritis treated with etanercept or disease-modifying anti-rheumatic drugs","volume":"32","author":"Emery","year":"2014","journal-title":"Clin Exp Rheumatol."},{"issue":"4","key":"10.1016\/j.ard.2026.05.033_bib0049","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s15010-024-02187-z","article-title":"Factors associated with severe infection in rheumatoid arthritis patients: lessons learned from the COVID-19 pandemic","volume":"52","author":"Embaby","year":"2024","journal-title":"Infection."},{"issue":"4","key":"10.1016\/j.ard.2026.05.033_bib0050","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1001\/jama.2023.11043","article-title":"Abatacept, cenicriviroc, or infliximab for treatment of adults hospitalized with COVID-19 pneumonia: a randomized clinical trial","volume":"330","author":"O'Halloran","year":"2023","journal-title":"JAMA."}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726003444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726003444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:52:16Z","timestamp":1788580336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726003444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":50,"alternative-id":["S0003496726003444"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.05.033","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A head-to-head comparison of abatacept and adalimumab in adults with early and dual seropositive rheumatoid arthritis plus HLA-DRB1 shared epitope: results from the randomised phase 3 AMPLIFIED trial","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}